{Reference Type}: Journal Article
{Title}: Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
{Author}: Shen D;Gong Y;Qian Y;Zhu J;Gao J;
{Journal}: J Int Med Res
{Volume}: 52
{Issue}: 5
{Year}: 2024 May
{Factor}: 1.573
{DOI}: 10.1177/03000605241247705
{Abstract}: Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). Ritonavir is a cytochrome P450 3A inhibitor and a P-glycoprotein inhibitor that increases the plasma concentration of tacrolimus and other medications. We describe the cases of two patients treated with nirmatrelvir/ritonavir: a patient who had undergone kidney transplantation and another with a history of hematopoietic stem cell transplantation. Toxic concentrations of tacrolimus were induced in both. This case series highlights the risk associated with the concomitant administration of tacrolimus and nirmatrelvir/ritonavir.